The system will be going down for regular maintenance. Please save your work and logout.

Show simple item record

dc.contributor.authorAbdelhameed, Farah
dc.contributor.authorKite, Chris
dc.contributor.authorLagojda, Lukasz
dc.contributor.authorDallaway, Alexander
dc.contributor.authorChatha, Kamaljit Kaur
dc.contributor.authorChaggar, Surinderjeet S.
dc.contributor.authorDalamaga, Maria
dc.contributor.authorKassi, Eva
dc.contributor.authorKyrou, Ioannis
dc.contributor.authorRandeva, Harpal S.
dc.date.accessioned2024-06-12T07:36:29Z
dc.date.available2024-06-12T07:36:29Z
dc.date.issued2024-05-29
dc.identifierhttps://chesterrep.openrepository.com/bitstream/handle/10034/628753/s13679-024-00574-z.pdf?sequence=2
dc.identifier.citationAbdelhameed, F., Kite, C., Lagojda, L., Dallaway, A., Chatha, K. K., Chaggar, S. S., Dalamaga, M., Kassi, E., Kyrou, I., & Randeva, H. S. (2024). Non-invasive scores and serum biomarkers for fatty liver in the era of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A comprehensive review From NAFLD to MAFLD and MASLD. Current obesity Reports, 13, 510–531. https://doi.org/10.1007/s13679-024-00574-zen_US
dc.identifier.issn2162-4968en_US
dc.identifier.doi10.1007/s13679-024-00574-zen_US
dc.identifier.urihttp://hdl.handle.net/10034/628753
dc.descriptionThe version of record of this article, first published in [Current Obesity Reports], is available online at Publisher’s website: http://dx.doi.org/10.1007/s13679-024-00574-zen_US
dc.description.abstractThe prevalence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide, making it the leading cause of liver related morbidity and mortality. Currently, liver biopsy is the gold standard for assessing individuals with steatohepatitis and fibrosis. However, its invasiveness, sampling variability, and impracticality for large-scale screening has driven the search for non-invasive methods for early diagnosis and staging. In this review, we comprehensively summarise the evidence on the diagnostic performance and limitations of existing non-invasive serum biomarkers and scores in the diagnosis and evaluation of steatosis, steatohepatitis, and fibrosis. Several non-invasive serum biomarkers and scores have been developed over the last decade, although none has successfully been able to replace liver biopsy. The introduction of new NAFLD terminology, namely metabolic dysfunction-associated fatty liver disease (MAFLD) and more recently metabolic dysfunction-associated steatotic liver disease (MASLD), has initiated a debate on the interchangeability of these terminologies. Indeed, there is a need for more research on the variability of the performance of non-invasive serum biomarkers and scores across the diagnostic entities of NAFLD, MAFLD and MASLD. There remains a significant need for finding valid and reliable non-invasive methods for early diagnosis and assessment of steatohepatitis and fibrosis to facilitate prompt risk stratification and management to prevent disease progression and complications. Further exploration of the landscape of MASLD under the newly defined disease subtypes is warranted, with the need for more robust evidence to support the use of commonly used serum scores against the new MASLD criteria and validation of previously developed scores. [Abstract copyright: © 2024. The Author(s).]en_US
dc.description.sponsorshipUnfundeden_US
dc.languageeng
dc.publisherSpringeren_US
dc.relation.urlhttps://link.springer.com/article/10.1007/s13679-024-00574-zen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceeissn: 2162-4968
dc.subjectMASLDen_US
dc.subjectObesityen_US
dc.subjectMetabolic dysfunction-associated fatty liver diseaseen_US
dc.subjectNAFLDen_US
dc.subjectNon-alcoholic fatty liver diseaseen_US
dc.subjectMetabolic dysfunction-associated steatotic liver diseaseen_US
dc.subjectBiomarkersen_US
dc.subjectFatty liveren_US
dc.subjectMAFLDen_US
dc.titleNon-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLDen_US
dc.typeArticleen_US
dc.contributor.departmentUniversity Hospitals Coventry and Warwickshire NHS Trust; University of Wolverhampton; Coventry University; University of Chester; Sowe Valley Primary Care Network; National and Kapodistrian University of Athens; Aston University; University of Derby; Agricultural University of Athensen_US
dc.identifier.journalCurrent Obesity Reportsen_US
dc.date.updated2024-06-11T01:36:41Z
dc.identifier.volume13
dc.date.accepted2024-05-14
rioxxterms.identifier.projectUnfundeden_US
rioxxterms.versionVoRen_US
dc.source.beginpage510–531
dc.date.deposited2024-06-12en_US


Files in this item

Thumbnail
Name:
s13679-024-00574-z.pdf
Size:
1.679Mb
Format:
PDF
Request:
Article - VoR

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0/